发布求助
文献互助 智能选刊 最新文献

Endocrinology and disorders : open access最新文献

筛选
英文 中文
Tamsulosin and Dementia in Old Age: is There Any Relationship? 坦索罗辛与老年痴呆：有关系吗？
Endocrinology and disorders : open access Pub Date : 2019-09-23 DOI: 10.24018/ejmed.2019.1.4.77
Rebecca Renata Lapenda do Monte, Karina de Andrade Vidal Costa, Arnaldo Santiago Nunes Junior, A. Rêgo, I. Filho
{"title":"Tamsulosin and Dementia in Old Age: is There Any Relationship?","authors":"Rebecca Renata Lapenda do Monte, Karina de Andrade Vidal Costa, Arnaldo Santiago Nunes Junior, A. Rêgo, I. Filho","doi":"10.24018/ejmed.2019.1.4.77","DOIUrl":"https://doi.org/10.24018/ejmed.2019.1.4.77","url":null,"abstract":"Tamsulosin is used to treat Benign Prostatic Hyperplasia (BPH), prescribed annually to about 12.6 million patients worldwide. It is an alpha-adrenergic antagonist that reduces the tone of the prostate smooth muscle involved in the pathophysiology of BPH. By acting on alpha 1A receptors, predominant in the prostate, tamsulosin also acts on receptors present in the brain. This study consisted of a literature review aimed at disseminating scientific knowledge about the relationship between the use of tamsulosin and the onset of dementia. Pubmed, Scopus, Scielo, Embase, and Web of Science studies involving dementia in patients using tamsulosin in the last five years were selected. The review showed a risk correlation and a higher incidence of dementia in treated patients. The risk ratio, when compared to other medicines, approached 1.20. In conclusion, it was identified the need for clinical trials with higher sampling power to increase relational significance due to the high prevalence of BPH and the extensive use of tamsulosin in elderly patients with the disease.","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44969187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impulse Control Disorder in a Patient with Invasive Prolactinoma on Dopamine agonist Therapy: A Case Report 多巴胺激动剂治疗侵袭性泌乳素瘤患者的冲动控制障碍：一例报告
Endocrinology and disorders : open access Pub Date : 2019-04-02 DOI: 10.31579/2640-1045/038
P. Dutt
{"title":"Impulse Control Disorder in a Patient with Invasive Prolactinoma on Dopamine agonist Therapy: A Case Report","authors":"P. Dutt","doi":"10.31579/2640-1045/038","DOIUrl":"https://doi.org/10.31579/2640-1045/038","url":null,"abstract":"Prolactinomas constitutes a major bulk of pituitary adenomas. All symptomatic prolactinomas require dopamine agonist (DA) therapy. Impulse control disorders (ICD) or pathological behaviours are rare adverse events described with use of DA. Herein we are describing a male patient with pathological gambling and doctor shopping following use of bromocriptine and higher dose of cabergoline.The pathological behaviour disappeard after debulking surgery, reduction in cabergoline dose and several sessions of counselling. Physicians prescribing DA should be aware of this potential adverse event.This should be emphasized to the patient and family members before starting DA and physician should be inquisitive for eliciting pathological behaviour on follow up.","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43781394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MiR-302: The Multifunctional MicroRNA MiR-302:多功能MicroRNA
Endocrinology and disorders : open access Pub Date : 2019-01-01 DOI: 10.31579/2640-1045/040
S. Ying
{"title":"MiR-302: The Multifunctional MicroRNA","authors":"S. Ying","doi":"10.31579/2640-1045/040","DOIUrl":"https://doi.org/10.31579/2640-1045/040","url":null,"abstract":"MicroRNAs (miRNAs) are short single-stranded noncoding RNAs (20- to 25-nucleotide (nt) long) representing a class of small regulatory RNAs. By inhibiting the translation of target mRNAs, miRNAs regulate gene expression posttranscriptionally and thus play an important role in a wide range of cellular processes. Currently, there are two known types of miRNAs: intergenic and intronic miRNAs. Biogenesis of an intergenic miRNA starts with the synthesis of a primary miRNA transcript (pri-miRNA) catalyzed by types-II or -III RNA polymerase (Pol-II/III). Pri-miRNAs are processed in the nucleus by the ribonuclease Drosha into a miRNA precursor (pre-miRNA) approximately 60-nt in length. After being transported into the cytoplasm, these pre-miRNAs are further processed into mature and functional miRNAs by the cytoplasmic ribonuclease Dicer. Mature miRNAs then associate with a number of proteins to form the RNA-induced silencing complex (RISC) that bind with target mRNAs having total or partial complementary sequences to the miRNAs and initiate the inhibition of subsequent protein translation via RNA interference (RNAi).","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70017428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ErbB2 and EphA3 as a novel prognostic and therapeutic target of Recurrent Non-functioning Pituitary Adenomas: A pilot study ErbB2和EphA3作为复发性无功能垂体腺瘤新的预后和治疗靶点:一项初步研究
Endocrinology and disorders : open access Pub Date : 2019-01-01 DOI: 10.31579/2640-1045/039
P. Dutta
{"title":"ErbB2 and EphA3 as a novel prognostic and therapeutic target of Recurrent Non-functioning Pituitary Adenomas: A pilot study","authors":"P. Dutta","doi":"10.31579/2640-1045/039","DOIUrl":"https://doi.org/10.31579/2640-1045/039","url":null,"abstract":"Non-functioning pituitary adenomas (NFPA) are 30% of all pituitary adenomas. Although benign in nature but they may be invasive and recurrent. Markers of recurrence are needed to guide patient management. Recteptor Tyrosine Kinases (RTK) may sereve as therapeutic marker for recurrence as they can targeted by already available tyrosine kinase inhibitors. To examine differential RTK phosphorylation pattern of recurrent NFPAs, we recruited 20 patients and grouped them as non-recurrent (n=10), and recurrent (n=10). Recurrence was determined by follow-up of 15 years. We then performed a membrane-based antibody array (ARY001B) for the determination of the relative phosphorylation of 49 tyrosine kinases in recurrent NFPAs. As the experiment was replicated on two set of membranes, each tyrosine kinase was represented in quadruples. Student’s t-test was performed to compare the means between two groups. We found ErbB2, PDGFR beta, SCFR, Trk, VEGFR1, VEGFR2, EphA3, and Alk significantly hyperphosphorylated in recurrent NFPAs. Out of these eight hyperphosphorylated tyrosine kinases ErbB2 and EphA3 were 1.6 (p=0.01) and 1.9 (p=0.002) times hyperphosphorylated in recurrent NFPAs. This result indicates that EphA3 may be an effective therapeutic target in recurrent NFPAs.","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":"76 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70017373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case Report of Cortisol-Secreating Adrenal Adenoma Causing Cushing Syndrome 肾上腺皮质醇分泌腺瘤致库欣综合征1例报告
Endocrinology and disorders : open access Pub Date : 2019-01-01 DOI: 10.31579/2640-1045/044
H. Radhi
{"title":"A Case Report of Cortisol-Secreating Adrenal Adenoma Causing Cushing Syndrome","authors":"H. Radhi","doi":"10.31579/2640-1045/044","DOIUrl":"https://doi.org/10.31579/2640-1045/044","url":null,"abstract":"Cushing syndrome is a state of prolonged exposure to excess cortisol production. Causes can be varied ranging from exogenous intake or endogenous production from a pituitary source due to overproduction of adrenocorticotropic hormone (ACTH) or due to over secretion from unilateral or bilateral adrenal glands. Cushing syndrome in an adult can present with proximal muscle weakness, facial plethora, wasting of the extremities with increased fat in the abdomen and face, wide purplish striae, bruising with no obvious trauma, and supraclavicular fat pads. Here, we report a 38 year old male who presented with suspicion of having Cushing syndrome due to his clinical manifestations and high cortisol levels. He presented to the clinic with new onset diabetes, severe hypertension, chronic abdominal pain and distension which was being investigating by different specialties. The patient underwent CT scan of the abdomen which show right adrenal adenoma and on examination, he was found to have proximal weakness and purple striae. Laboratory data showed high morning cortisol, 24 urine free cortisol and ACTH levels which were strongly suggestive of ACTH independent Cushing syndrome.","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70017542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Education and Exercise on the Quality of Life among Adults with Chronic Renal Disease 成人慢性肾脏病患者生活质量的教育与锻炼
Endocrinology and disorders : open access Pub Date : 2018-11-12 DOI: 10.31579/2640-1045/037
M. D’Souza, Eilean Victoria Lazarus Rathinasamy
{"title":"Education and Exercise on the Quality of Life among Adults with Chronic Renal Disease","authors":"M. D’Souza, Eilean Victoria Lazarus Rathinasamy","doi":"10.31579/2640-1045/037","DOIUrl":"https://doi.org/10.31579/2640-1045/037","url":null,"abstract":"Objective: Evaluate the effectiveness of education and exercise on the quality of life among adults with chronic renal disease (CRD) on hemodialysis post-intervention (4 and 8 weeks). Methods: An evaluative true intervention approach was used. An ethical approval was obtained from the institutional ethics committee. A random sample of 150 patients (75 in intervention and 75 in control group) with CRD receiving dialysis was selected based on the inclusion criteria. The intervention group received interactive education and supervised exercises. RAND health-related kidney disease QOL (KDQOL) questionnaire was used. Results: Mean scores for the Kidney Disease and general QOL sub-scales among the intervention group were higher and statistically significant (p<0.01) compared to the control group. Conclusion: Education and exercise was shown to have a positive effect on the physical and mental health among the adults.","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41656088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Thyroid Storm: Emergency Care for Thyrotoxicosis 甲状腺风暴:甲状腺毒症的紧急护理
Endocrinology and disorders : open access Pub Date : 2018-09-16 DOI: 10.31579/2640-1045/030
Sam Hamseley
{"title":"Thyroid Storm: Emergency Care for Thyrotoxicosis","authors":"Sam Hamseley","doi":"10.31579/2640-1045/030","DOIUrl":"https://doi.org/10.31579/2640-1045/030","url":null,"abstract":"Thyroid hormones affect all organ systems and, in excess, can cause increased metabolic rate, heart rate, ventricle contractility, and gastrointestinal motility as well as muscle and central nervous system excitability. Thyroid storm is the extreme manifestation of thyrotoxicosis with an estimated incidence of 0.20 per 100,000 per year among hospitalized patients in Japan. The mortality of thyroid storm without treatment ranges from 80% to 100%; but with treatment, the mortality rate is between 10% and 50%. The diagnostic strategy for thyroid storm may take into consideration Burch–Wartofsky scoring or Akamizu's diagnostic criteria. Multiple treatment aims need to be addressed in managing thyroid storm effectively. This paper puts together all aspects to be considered for the management of hyperthyroidism and thyroid storm during the acute and emergency phase as well as consideration of special populations.","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42034678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-Diabetic Agent: Involvement in Hepatic Fat Metabolism In Pioglitazone-Treated Type 2 Diabetic Patients 抗糖尿病药物:参与吡格列酮治疗的2型糖尿病患者肝脏脂肪代谢
Endocrinology and disorders : open access Pub Date : 2018-09-16 DOI: 10.31579/2640-1045/028
David Spacey
{"title":"Anti-Diabetic Agent: Involvement in Hepatic Fat Metabolism In Pioglitazone-Treated Type 2 Diabetic Patients","authors":"David Spacey","doi":"10.31579/2640-1045/028","DOIUrl":"https://doi.org/10.31579/2640-1045/028","url":null,"abstract":"Pioglitazone (brand name Actos) is a prescription drug of the thiazolidinedione (TZD) class with hypoglycemic (antihyperglycemic, antidiabetic) action to treat diabetes. Pioglitazone is one of the antidiuretic agents used in the management of type 2 diabetes mellitus (DM). The effect of pioglitazone on blood glucose, lipid profile, liver enzymes and weight has been shown with conflicting results. In this study we aim to evaluate the effect of pioglitazone on the weight, lipid profile and liver enzymes in patients with DM. Pioglitazone is used to lower blood glucose levels in the treatment of diabetes mellitus type 2 (T2DM) either alone or in combination with a sulfonylurea, metformin, or insulin.","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43351436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological Study of Proliferative Diabetic Retinopathy Treatments for the Vision-Threatening Complications of Diabetic Macular Edema 增殖性糖尿病视网膜病变的流行病学研究糖尿病黄斑水肿危及视力并发症的治疗
Endocrinology and disorders : open access Pub Date : 2018-09-16 DOI: 10.31579/2640-1045/029
A. Petrovich
{"title":"Epidemiological Study of Proliferative Diabetic Retinopathy Treatments for the Vision-Threatening Complications of Diabetic Macular Edema","authors":"A. Petrovich","doi":"10.31579/2640-1045/029","DOIUrl":"https://doi.org/10.31579/2640-1045/029","url":null,"abstract":"Diabetic retinopathy (DR) is a leading cause of vision-loss globally. Of an estimated 285 million people with diabetes mellitus worldwide, approximately one third have signs of DR and of these, a further one third of DR is vision-threatening DR, including diabetic macular edema (DME). The identification of established modifiable risk factors for DR such as hyperglycemia and hypertension has provided the basis for risk factor control in preventing onset and progression of DR. Additional research investigating novel risk factors has improved our understanding of multiple biological pathways involved in the pathogenesis of DR and DME, especially those involved in inflammation and oxidative stress. Variations in DR prevalence between populations have also sparked interest in genetic studies to identify loci associated with disease susceptibility. Diabetic retinopathy (DR) is a leading cause of vision-loss globally. Of an estimated 285 million people with diabetes mellitus worldwide, approximately one third have signs of DR and of these, a further one third of DR is vision-threatening DR, including diabetic macular edema (DME). The identification of established modifiable risk factors for DR such as hyperglycemia and hypertension has provided the basis for risk factor control in preventing onset and progression of DR. Additional research investigating novel risk factors has improved our understanding of multiple biological pathways involved in the pathogenesis of DR and DME, especially those involved in inflammation and oxidative stress. Variations in DR prevalence between populations have also sparked interest in genetic studies to identify loci associated with disease susceptibility. In this review, major trends in the prevalence, incidence, progression and regression of DR and DME are explored, and gaps in literature identified. Established and novel risk factors are also extensively reviewed with a focus on landmark studies and updates from the recent literature.","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43486408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reproductive Endocrinology: Pregnancy and Postpartum Thyroid Disorders in Women 生殖内分泌学:妇女妊娠和产后甲状腺疾病
Endocrinology and disorders : open access Pub Date : 2018-09-16 DOI: 10.31579/2640-1045/031
E. Rogers
{"title":"Reproductive Endocrinology: Pregnancy and Postpartum Thyroid Disorders in Women","authors":"E. Rogers","doi":"10.31579/2640-1045/031","DOIUrl":"https://doi.org/10.31579/2640-1045/031","url":null,"abstract":"Reproductive Endocrinology is a medical specialty for infertility, menopause, and other issues with reproductive hormones. Reproductive endocrinologists are OB/GYN (obstetrics and gynecology) doctors with special training to help both men and women with problems related to reproductive hormones. Sometimes, this specialty is called reproductive endocrinology and infertility because much of their work focuses on helping women to become pregnant and carry a baby to term.","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42375066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信